Skip to main content
Quest Diagnostics

Changes in Guillain-Barre Syndrome-Associated Ganglioside Antibody Test Results at a National Clinical Laboratory During the COVID-19 Pandemic

American Academy of Neurology 2022 (AAN 2022)

April 2-7 , 2022, Seattle, WA

Poster presentation: Changes in Guillain-Barre Syndrome-Associated Ganglioside Antibody Test Results at a National Clinical Laboratory During the COVID-19 Pandemic

Authors: Racke M, Lorenz R, Niles J, Kaufman H

Specialties: Neurology

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.